

Product Name: BMS-777607 Revision Date: 01/10/2021

Product Data Sheet

BMS-777607

Cat. No.:	A5703
CAS No.:	1025720-94-8
Formula:	C25H19CIF2N4O4
M.Wt:	512.89
Synonyms:	
Target:	Tyrosine Kinase
Pathway:	c-MET
Storage:	Store at -20°C
	010

Solvent & Solubility

	\geq 25.65 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg
		1 mM	1.9497 mL	9.7487 mL	19.4974 mL
		5 mM	0.3899 mL	1.9497 mL	3.8995 mL
		10 mM	0.1950 mL	0.9749 mL	1.9497 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	C-Met inhibitor, potent and selective			
IC ₅₀ & Target	3.9 nM (c-Met), 1.1 nM (A	3.9 nM (c-Met), 1.1 nM (Axl), 1.8 nM (Ron), 4.3 nM (Tyro3)		
	Cell Viability Assay			
	Cell Line:	KHT cells		
	Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining		
In Vitro		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or		
		shake it in the ultrasonic bath for a while. Stock solution can be stored below		
		-20 °C for several months.		
	Reacting conditions:	10 μM; 2, 24 and 96 hrs		
		1 www.apexbt.com		

In the highly metastatic murine KHT cells, treatment of BMS-777607 (~ 10 µM) for 2 hrs potently eliminated basal levels of autophosphorylated c-Met. Animal experiment Animal models: Mice bearing KHT xenografts Dosage form: 10 ~ 25 mg/kg; p.o.; q.d. Applications: In mice bearing KHT xenografts, BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.	-			
In Vivo In Viv		Applications:	In the highly metastatic murine KHT cells, treatment of BMS-777607 (~ 10 $\mu\text{M})$	
In Vivo In Viv			for 2 hrs potently eliminated basal levels of autophosphorylated c-Met.	
Animal models: Mice bearing KHT xenografts Dosage form: 10 ~ 25 mg/kg; p.o.; q.d. Applications: In mice bearing KHT xenografts, BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		Animal experiment		
In Vivo In Vivo Dosage form: 10 ~ 25 mg/kg; p.o.; q.d. In mice bearing KHT xenografts, BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.	In Vivo	Animal models:	Mice bearing KHT xenografts	
In Vivo Applications: In mice bearing KHT xenografts, BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		Dosage form:	10 ~ 25 mg/kg; p.o.; q.d.	
In Vivo In Vivo Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		Applications:	In mice bearing KHT xenografts, BMS-777607 (25 mg/kg/day) decreased the	
Import hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		PErson	number of KHT lung tumor nodules (28.3%), improved the morphological	
Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		Sector Date	hemorrhage, and significantly impaired the metastatic phenotype, without	
Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.			apparent systemic toxicity.	
slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
system error and it is normal.			slightly differ with the theoretical value. This is caused by an experimental	
			system error and it is normal.	

Product Citations



1. White SM, Avantaggiati ML, et al. "YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells." Dev Cell. 2019 May 6;49(3):425-443.e9.PMID:31063758

See more customer validations on www.apexbt.com.

References

[1]. Dai Y, Bae K, Pampo C, Siemann DW. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis. 2012 Mar;29(3):253-61.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.





APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

